CBIO

Crescent Biopharma is a clinical-stage oncology biotechnology company developing CR-001, a PD-1 x VEGF bispecific antibody designed to serve as an immuno-oncology backbone, alongside a portfolio of antibody drug conjugates including CR-002, a PD-L1-targeting ADC with a topoisomerase inhibitor payload and CR-003. The company initiated a global Phase 1/2 trial of CR-001 in February 2026 and plans to initiate CR-002 and CR-003 monotherapy trials in 2026, with the intention of combining these therapies to create synergistic oncology combinations across multiple solid tumor indications.

Pipeline

Catalyst Calendar